Cash, cash equivalents, and short-term investments totaled $107.6 million as of December 31, 2025. The Company expects its cash to fund operations into the second half of 2028, through the anticipated initial clinical proof-of-concept readout from KOMODO-1.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BOLD:
- Boundless Bio Advances New Breast Cancer Drug BBI-940 Into First-in-Human Trial
- Boundless Bio announces FDA accepted IND application of BBI-940
- Boundless ceases enrollment of Phase 1/2 Potentiate trial of BBI-355, BBI-825
- Boundless Bio Terminates Early-Stage BBI-825 Cancer Trial: What Investors Should Know